Progress in immunotherapy rituximab

Saudi Medical Journal

Volumn 28, Issue 11, 2007, Pages 1635-1644

  El Habbash, Manal M ^a   Alwindi, Abukris M ^a  

^a Tripoli Medical Centre   (Libyan Arab Jamahiriya)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CD20 ANTIGEN; CHLORAMBUCIL; COMPLEMENT COMPONENT C1Q; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; MELPHALAN; MITOXANTRONE; PACLITAXEL; PREDNISOLONE; PREDNISONE; RITUXIMAB; TOPOTECAN; VINBLASTINE; VINCRISTINE SULFATE;

ADVANCED CANCER; ANGIONEUROTIC EDEMA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LEUKEMIA; B LYMPHOCYTE ACTIVATION; BLOOD TOXICITY; BRONCHOSPASM; CANCER IMMUNOTHERAPY; CANCER PAIN; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; FLUSHING; FOLLICULAR LYMPHOMA; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOTENSION; HYPOXIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHODGKIN LYMPHOMA; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; SIDE EFFECT; THROAT IRRITATION; TUMOR LYSIS SYNDROME; URTICARIA; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; STEM CELL TRANSPLANTATION;

EID: 36949035384     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Nadler LM, Ritz J, Hardy R, Pesando M, Schlossman SF, Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 1984; 67:134-140.
2. Anderson KC, Bates MP, Slaughenhout BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 1984; 63: 1424-1433.
3. Treon SP, Kelliher A, Keele B, Frankel S, Emmanouilides C, Kimby E, et al. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: Therapeutic applications and considerations. Semin Oncol 2003; 30: 248-252.
4. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard E, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
5. Maloney DG, Smith B, Appelbaum FR. The antitumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD 20 positive non-Hodgkin lymphoma cell lines. Blood 1996; 88: 637a.
6. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171: 1581-1587.
7. Maloney DG, Liles Tm, Czerwinski DK, Waldichuck C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-2466.
8. Berinstein NL, Grillo-López AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995-1001.
9. Jensen M, Winkler U, Manzke O, Diehl V, Engert A, Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998; 77: 89-91.
10. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
11. Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Sem Oncol 2002; 29: 36-40.
12. Ardesha KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial. Lancet 2003; 362: 516-522.
13. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276.
14. Robert Marcus, Kevin Imrie, Andrew Belch, David Cunningham, Eduardo Flores, John Catalano, et al. M39021-an international multicenter randomised, open-label phase trial comparing Rituximab added to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkin's lymphoma: Final analysis. Blood 2003; 102: 28a.
15. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade of follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711-4716.
16. Marcus R, imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423.
17. Wolfgang Hiddemann, Martin H. Dreyling, Roswitha Forstpointer, Michael Kneba, Bernhard Woermann, Eva Lengfelder, et al. Combined immunochemotherapy (R-CHOP) significantly improve time to treatment failure in first - line therapy of follicular lymphoma: Results of a prospective randomised trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 2003; 102: 104a.
18. Martinelli G, Laszlo D, Bertolini F, Pastano R, Mancuso P, Calleri A, et al. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. Br J Hematology 2003; 123: 271-277.
19. Hainsworth D, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, et al. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: A phase II trial of the minnie pearl cancer research network. J Clin Oncol 2005; 23: 1500-1506.
20. Zinzani PL. A multicenter randomised trial of Fludarabine and Mitoxantrone (FM) plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma (FL). Blood 2002; 100: 93a.
21. McLaughlin P, Rodriguez MA, Hagemeister FB, Romaguera J, Sarris Andreas H, Yonnes Anas, et al. Stage IV indolent Lymphoma: Randomised study of concurrent vs. sequential use of FND chemotherapy (Fludarabine, Mitxantrone, dexamethasone) and Rituximab monoclonal antibody therapy with interferon maintenance. Proc Am Soc Clin Oncol 2003; 22: 564.
22. Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856-862.
23. Colombat P, Salles G, Brousse N, Efrekhari P, Soubeyran P, Delwail V, et al. Rituximab (anti-CD-20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101-106.
24. Wirzig TE, Vukey AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005; 23: 1103-1108.
25. Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclanal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135-3143.
26. Ghielmini M, Schmitz S-FH, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patiens with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 2004; 103: 4416-4423.
27. Hainsworth JD, Litchy S, Burris HA III, Scullin DCJr, Corso SW, Yardley DA, et al. Rituximab as first-line and maintenane therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261-4267.
28. Martin H. Dreyling, Roswitha Forstpointner, Roland Repp, Sandra Hermann, Annette Haenel, Bernd Metzner, et al. Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in current follicular and mantle cell lymphoma - follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 2003; 102: 103a
29. Sivaraman S, Venugopal P, Ranganathan R, Deshpande CG, Huang X, Jajeh A. Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia. Cytokines Cell Mol Ther 2002; 6: 81-87.
30. Kimby E, Geisler C, Hagberg H, Holte H, Lehtinen T, Sundstrom C, et al. Rituximab as single agent and in combination with interferon-[alpha]-2a as treatment of untreated and first repalse follicular or other low-grade lymphomas. A randomized Phase II study. Ann Oncol 2003; 13: S85.
31. Coiffier B, H erbrecht R, Morel P, Salles G, Tilly H, Sebban C, et al. GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3 years median follow-up with an analysis according to co-morbidity factors. Hematol J 2003; 4 (Suppl 2): 111.
32. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia. J Clin Oncol 2003; 2005: 5027-5033.
33. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, et al. Phase III trial of randomization to maintenance Rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 102: 8a.
34. Connor PM, Horning S, Valente N, Combs D, Ng C, et al. Pharmacokinetic comparison of two different dosing regimens of Rituxan plus CHOP (R-CHOP) IN ECOG/CALGB/SWOG (E4494) and GELA LNH -98 trials of older patients (pts) with diffuse large B-cell (DLBCL) lymphoma. Blood 2003; 102: 412a.
35. Pfreundschuh MGM, Trumper Lorenz, Ma David, Sterborg A, Pettengell Ruth Trneny Marek, et al. Randomized Intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis. Proc Am Soc Clin Oncol 2004; 23: 6500.
36. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684-3688.
37. Younes A, McLaughlin P, Hagemeister FB, Pro B., Samaniego F., Romaguera JE. et al. Addition of rituximab to Taxol plus Topotecan (TTR) improve response rate and complete remission rate in patients with relapsed/ refractory aggressive B-cell lymphoma. Ann Oncol 2002; 13 (Suppl 2): 74.
38. Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ, Keith E, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103: 777-783.
39. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-Term Results of the R-CHOP Study in the treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology 2005; 23: 4117-4126.
40. Hiddemann W, Unterhalt M, Dreyling M, Hossfeld DK, Lengfelder E, Metzner B, et al. The addition of rituximab (R) to combination chemotherapy (CT) significantly improve the prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG). Blood 2002; 100: 92a.
41. Mangel J, Leitch HA, Connors JM, Buckstein R, Imrie K, Spaner D, et al. Intensive chemotherapy and autologous stemcell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: A matched pair analysis. Ann Oncol 2004; 15: 283-290.
42. Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pitotti S, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autograffing (R-HDS regimen). Blood 2003; 102: 749-755.
43. Itälä M, Geisler CH, Kimby E, Juvonen E, Tjonnfjord G, Karlsson K, et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: Results from a Nordic multicentre study. Eur J Haematol 2002: 69; 129-134.
44. Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: Relationship to in expression in chronic lymphocytic leukemia: Relationship to in vivo rituximab resistance. J Clin Oncol 2003; 21: 1466-1471.
45. O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165-2170.
46. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153-2165.
47. John C. Byrd, Bercedis L. Peterson, Vicki A. Morrison, Kathleen Park, Robert Jacobson, Eva Hoke, et al. Randomized phase 2 study of fludarabine in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003a; 101: 6-14.
48. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, et al. Phase 2 study of a combined immunochemotherapy using rituximab and Fludarabine in patients with chronic lymphocytic leukemia. Blood 2003; 101: 6-14.
49. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F et al. Early results of an immunochemotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab Therapy for chronic lymphocytic leukemia. J Clin Orthod 200; 23: 4079-4087.
50. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, et al. Chemoimmunotherapy with fludarabine, cyclophosphamine, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070-4078.
51. Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325-3333.
52. Buckstein R, Imrie K, Spaner D, Potichnyj A, Robinson JB, Nanji S, et al. Stem cell function and engraftment is not affected by in vivo purging with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 1999; 26: 115-112.
53. Rena J. Buckstein, J. Mangel, K. Imrie, D. Spaner, M. Crump, N. Pennell, et al. High dose therapy/ASCT consolidated with rituximab and or alpha interferon immunotherapy for relapsed follicular lymphoma prolongs progression free survival and achieved durable molecular remission. Blood 2002; 100: 647a-648a.
54. Stephan H.K. Oertel, Karin Zeidler, Matthias Papp-Vary, Petra Reinke, Sven Jonas, Eric Verschuuren, et al. Monotherapy with the anti-CD20 antibody rituximab in patients with post-transplant lymph-proliferative disease. Results of a multicenter phase II study. Blood 2003; 102: 413a.
55. Steven P. Treon, Parveen Wasi, Christos A. Emmanouilides Stanley R. Frankel, Eva Kimby, Andrew Lister, et al. Combination therapy with rituximab and Fludarabine is highly active in Waldenstrom's macroglobulinaemia. Blood 2002; 100: 112a.
56. Michele Spina, Cecilia Simonelli, Emanuela Vaccher, Giuseppe Rossi, Ulrich Jaeger, Joseph A. Sparano, E et al. Rituximab and infusional Cyclophosphamide, doxorubicin and etoposide (CDE) in combination with HAART: A safe and highly active regimen in HIV-related non-Hodgkin' lymphoma. Blood 2003; 102: 123a.
57. Rehwald U, Schulz H, Reiser M, Sieber M, Staak JO, Morschhauser F, et al Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: Results of a phase 2 trail of the German Hodgkin Lymphoma Study Group. Blood 2003; 101: 420-424.
58. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriquez MA, Fiumara P, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003; 98: 310-314.
59. Younes A, McLaughlin P, Fayad L, Goy A, Medeiros L, Pro B, et al Rituximab plus ABVD therapy for newly diagnosed patients with classical Hodgkin lymphoma; a novel combination program targeting the cancer cells and the reactive B-cells in the microenvironment. Annals of Oncology 2005; 196: S16.
60. Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, et al. CD20-directed serotherapy in patients with multiple myeloma: Biologic considerations and therapeutic applications. J Immunother 2002; 25: 72-81.
61. Zinzani PL, Ascani S, Piccaluga PP, Bendandi M, Pileri S, Tura S. Efficacy of rituximab in hairy cell leukemia treatment. J Clin Oncol 2000; 18: 3875-3877.
62. Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M, et al. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 2001; 86: 1046-1050.
63. Layios N, Van Den Neste E, Jost E, Deneys V, Scheiff JM, Ferrant A. Remission of severe cold agglutinin disease after Rituximab therapy. Leukemia 2001; 15: 187-188.
64. Patel K, Berman J, Ferber A, Caro J. Refractory autoimmune thrombocytopenic purpura treatment with Rituximab. Am J Hematol 2001; 67: 59-60.
65. Rai KR, Gupta NK, Janson D, Patel DV, Ahmed I, Kavuru S. Rituximab, Cyclophosphamide and decadron combination is highly effective in auto-immune hemolytic anemia associated with chronic lymphocytic leukemia. Blood 2000; 96: S831.
66. Nichola Cooper, Robert Stasi, Michael Feuerstein, James B. Bussel. Transient B cell depletion with rituximab, an anti CD20 monoclonal antibodym, resulted in lasting complete response in 16/57 adults with refractory immune thrombocytopenic purpura. Blood 2002; 100: 52a.
67. Giagounidis AA, Anhuf J, Schneider P, Germing U, Sohngen D, Quabeck K, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with then anti-CD20 monoclonal antibody rituximab: A pilot study. Eur J Haematol 2002; 69: 95-100.
68. Emery P. Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment; results of a phase IIB randomized, double-blind, placebo-controlled, dosing-ranging trail. Arthritis Rheumatism 2006, 54: 1390-1400.
69. Edwards JC, Szczepanski L, SzechinskiJ, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581.